LDN for Sjögren Disease: What the Evidence Shows About Fatigue, Pain, and Dryness

Sjögren disease can be reduced online to two symptoms: dry eyes and dry mouth. For many people, that description misses the real burden. Fatigue, joint or muscle pain, sleep disruption, cognitive complaints, neuropathy, and systemic organ involvement may matter just as much as dryness.

That symptom burden helps explain the interest in low-dose naltrexone, commonly called LDN. LDN is sometimes discussed as an off-label option for pain, fatigue, and inflammatory or neuroimmune symptoms. It is also frequently grouped into broad claims about “calming autoimmunity.” The direct Sjögren evidence, however, remains much smaller than the online conversation suggests.

As of September 2026, the published direct evidence consists of three patients described in two case-report papers. Those reports include encouraging individual signals, particularly for fatigue and pain. They do not establish a predictable treatment effect, and they do not show that LDN restores tear or saliva production, prevents systemic complications, or modifies the underlying disease.

Considering LDN for a specific symptom or functional goal? Explore Scripx low-dose naltrexone options, review LDN medication interactions, or contact Scripx for a pharmacist-supported medication discussion. LDN is off label for Sjögren disease. Opioid exposure, tramadol, buprenorphine, methadone, opioid-containing cough or diarrhea products, liver history, pregnancy planning, and upcoming procedures require individualized review.

The Direct Answer:  Is LDN Proven for Sjögren Disease?

No. LDN is not FDA approved for Sjögren disease, and no randomized, placebo-controlled Sjögren trial has established its efficacy.

The most accurate conclusion is narrower:

• One 2019 case report described a patient who reported meaningful improvement in fatigue and pain, but not in dry eyes or dry mouth.
• A 2020 paper added two patients with reported clinical improvement, including joint symptoms and, in one patient, fatigue or broader well-being signals.
• The reports were uncontrolled and involved individualized treatment, dose changes, background therapy, and subjective outcomes.
• A 2023 review of LDN in rheumatologic diseases identified the same three Sjögren cases, not a larger controlled evidence base.
• Johns Hopkins’ Sjögren Center characterizes the evidence as anecdotal case reports and notes that LDN has not been formally studied in placebo-controlled Sjögren trials.

That is enough to justify research interest and a careful clinician-patient conversation. It is not enough to promise that LDN will relieve symptoms or alter Sjögren disease.

Why “Sjögren Disease” Is the Preferred Term

Many people still search for “Sjögren’s syndrome,” and that phrase remains useful for SEO and patient recognition. Current expert nomenclature increasingly favors Sjögren disease, or SjD, because this is a defined systemic autoimmune disease rather than merely a collection of symptoms.

The distinction matters. Sjögren can affect moisture-producing glands, but it can also involve the joints, peripheral and autonomic nervous systems, lungs, kidneys, skin, blood vessels, and other organs. Treatment decisions therefore depend on the manifestation being targeted. A therapy that might affect pain or fatigue should not automatically be described as treating gland dysfunction, neuropathy, lung disease, vasculitis, lymphoma risk, or systemic disease activity.

What the 2019 Case Report Actually Found

The first peer-reviewed report described a 47-year-old woman with long-standing dry eyes, dry mouth, joint pain, fatigue, elevated inflammatory measures, and a positive rheumatoid factor. She was described as having suspected Sjögren disease.

After LDN was introduced and adjusted, the patient reported significant improvement in fatigue and pain within approximately two weeks. Some inflammatory markers also changed during the treatment course.

The most important limitation is often lost in summaries: the patient did not report a significant change in dry eyes or dry mouth.

That single observation creates a useful evidence boundary. The case may support further investigation of fatigue, pain, or inflammatory signals. It does not demonstrate restored lacrimal or salivary gland function. It also cannot separate the effect of LDN from natural symptom fluctuation, expectation, concurrent care, laboratory variability, or other confounding factors.

The original report is available through PubMed. The LDN Research Trust abstract page can help patients and clinicians discover the publication, but it should remain a supplemental education source rather than independent proof.

The 2020 Paper Added Two Patients, Not a Trial

A second peer-reviewed paper described two additional women with documented Sjögren disease.

One was a 24-year-old woman with dry eyes, dry mouth, joint pain, fatigue, headache, elevated inflammatory measures, and a positive anti-SSA antibody. The other was a 66-year-old woman with dry eyes, dry mouth, joint pain, and elevated anti-SSA and anti-SSB antibodies. The authors reported clinical improvement, including joint-symptom improvement and, in one case, broader symptom or fatigue improvement.

These reports are relevant because they show that the initial case was not the only published individual experience. They are still case reports:

• There was no placebo group.
• There was no blinded outcome assessment.
• The number of patients was two.
• Background treatment and individual titration complicate attribution.
• The reports did not establish reliable improvement in tear or saliva production.
• The reports did not establish prevention of organ involvement or long-term disease modification.

The paper is indexed on PubMed. A 2023 review of LDN in rheumatologic diseases confirmed that the Sjögren literature consisted of three case descriptions and called for larger, reproducible studies. That review is also available through PubMed.

Three Patients Are a Signal, Not an Effect Size

Case reports can be clinically useful. They may identify an unexpected response, generate a hypothesis, and motivate a controlled trial. What they cannot tell us is how often a response occurs.

From three selected published patients, readers cannot reliably estimate:

• the likelihood of fatigue improvement;
• the average change in pain;
• how quickly improvement should occur;
• how long any benefit lasts;
• which patient characteristics predict response;
• the rate of nonresponse or symptom worsening;
• whether changes exceed placebo effects or natural fluctuation;
• whether LDN changes objective gland function or systemic disease activity.

Publication bias matters as well. Unusual or favorable responses are more likely to be written up than routine nonresponse. A case-report series should therefore be treated as an early signal, not a response rate.

Fatigue, Pain, and Dryness Are Different Outcomes

EULAR recommendations organize Sjögren management around a central symptom triplet: dryness, fatigue, and pain, followed by evaluation and treatment of systemic disease. Those categories are connected, but they are not interchangeable.

Fatigue

Fatigue in Sjögren can have multiple contributors, including inflammatory activity, poor sleep, pain, depression or anxiety, anemia, thyroid disease, medication effects, autonomic dysfunction, deconditioning, and overlapping fibromyalgia or sleep disorders. A reported improvement in one patient does not identify which pathway changed.

A responsible treatment plan should define fatigue in functional terms. Examples include the ability to complete a workday, maintain a walking routine, prepare meals, or recover after activity. It should also evaluate other treatable contributors rather than attributing all fatigue to Sjögren.

Pain

Pain may reflect inflammatory arthritis, noninflammatory arthralgia, myofascial pain, fibromyalgia, small fiber neuropathy, large fiber neuropathy, or another cause. Those mechanisms may require different treatment pathways.

The 2026 clinical practice guideline for peripheral nervous system manifestations in Sjögren recommends established symptom-directed and disease-directed approaches based on the neuropathy type and severity. LDN is not presented as an evidence-based replacement for those pathways. Readers with burning pain, numbness, weakness, imbalance, or progressive neurologic symptoms need appropriate neurologic and rheumatologic evaluation.

Dryness

Dry eyes and dry mouth are not merely comfort issues. Ocular surface disease may threaten vision, while reduced saliva increases the risk of dental caries, oral infection, difficulty swallowing, and nutritional problems.

Current Sjögren management uses symptom-specific evaluation and therapy, including ocular treatments, oral-hygiene and caries-prevention strategies, saliva-support measures, and medications that stimulate secretion when clinically appropriate. The 2019 LDN case did not show meaningful improvement in dryness, and the University of Pennsylvania Sjögren Center notes that naltrexone has been studied mainly for pain and fatigue syndromes rather than mucosal dryness.

LDN should not be presented as a substitute for ophthalmology, dentistry, oral medicine, rheumatology, or established dryness management.

A Better Question Than “Did My Inflammation Go Down?”

The case reports discussed inflammatory markers, which can make LDN sound like a proven immune-modifying therapy. That conclusion is not supported.

Markers such as erythrocyte sedimentation rate or C-reactive protein may change for many reasons. They do not directly measure tear production, salivary flow, glandular injury, neuropathy, pulmonary disease, lymphoma risk, or the full systemic activity of Sjögren.

In research and specialty care, objective systemic disease activity and patient-reported symptoms are measured separately. A person can feel better without evidence of disease modification, and a laboratory value can change without a meaningful improvement in daily function.

For LDN, a change in an inflammatory marker in a case report should be described as an observation. It is not proof that the medication suppresses Sjögren autoimmunity or prevents future complications.

Can LDN Replace Hydroxychloroquine or Other Established Care?

No comparative evidence supports replacing established Sjögren care with LDN.

Even established medications have a nuanced evidence base. For example, the randomized JOQUER trial did not meet its primary endpoint for hydroxychloroquine monotherapy, yet hydroxychloroquine remains used in selected patients, particularly for musculoskeletal manifestations and individualized clinical reasons. Newer combinations and investigational agents are also being studied with disease-specific outcome measures.

The lesson is not that one treatment “works” and another does not. It is that Sjögren care is manifestation-specific. Dryness management, inflammatory arthritis, neuropathy, lung disease, vasculitis, and other systemic complications require different evidence, monitoring, and specialty expertise.

LDN may be discussed as an off-label adjunct for a defined symptom goal after medication review. It should not be marketed as equivalent to hydroxychloroquine, immunomodulatory therapy, biologic therapy, ocular treatment, dental prevention, or systemic disease monitoring.

Opioid Exposure Is the Most Important Medication-Safety Gate

Naltrexone is an opioid antagonist. FDA-approved naltrexone labeling states that it blocks opioid effects, is contraindicated in patients receiving opioid analgesics, and can precipitate withdrawal in someone who is opioid dependent.

The medication review should include more than chronic pain prescriptions. Relevant exposure may include:

• hydrocodone, oxycodone, morphine, codeine, fentanyl, or other opioid analgesics;
• tramadol;
• methadone or buprenorphine;
• opioid-containing cough preparations;
• opioid-containing antidiarrheal products;
• recent emergency-department or dental opioid use;
• a planned procedure that may require opioid pain control.

The current DailyMed naltrexone label also warns that attempts to overcome opioid blockade can be dangerous. Patients should not create their own washout plan or stop prescribed opioid therapy to start LDN. The timing and safety plan belong with the prescribing clinician.

Procedures, Dental Care, and Sjögren Require Advance Planning

Sjögren can make dental and oral procedures especially relevant because dry mouth raises dental risk. Some procedures may involve opioid analgesia or sedation. A person taking naltrexone should tell the dentist, surgeon, anesthesiologist, emergency clinician, and pharmacist before treatment.

Advance coordination allows the care team to determine whether LDN should be held, what nonopioid options are appropriate, and how pain will be managed if opioid analgesia becomes necessary. Patients should never assume that a low dose is too small to matter.

The GLP-1 Crossover: Separate Indication, Shared Symptom Management

Semaglutide and tirzepatide may be prescribed for separate FDA-approved metabolic indications in eligible patients. They are not established treatments for Sjögren disease, dryness, autoimmune activity, neuropathy, or LDN responsiveness. No controlled evidence establishes an LDN-plus-GLP-1 combination as a Sjögren treatment or enhanced weight-loss protocol.

The crossover is still clinically relevant because treatment effects may overlap with Sjögren symptoms.

Hydration and dryness

Current Wegovy and Zepbound labeling warns about gastrointestinal adverse reactions and acute kidney injury related to volume depletion. Nausea, vomiting, diarrhea, constipation, or reduced intake can make hydration and oral comfort harder to maintain. That does not mean GLP-1 therapy directly causes Sjögren dryness, but it can complicate symptom management and medication attribution.

Nutrition and fatigue

Reduced appetite may be expected during GLP-1 therapy. Inadequate protein, calories, or fluids can also worsen weakness, dizziness, fatigue, and exercise tolerance. When fatigue changes, clinicians should consider the timing of GLP-1 initiation or escalation, oral intake, sleep, disease activity, and other medications before assigning the change to LDN or Sjögren.

Delayed gastric emptying and oral medications

The 2026 Wegovy and Zepbound labels state that these medicines delay gastric emptying and may affect the absorption of concomitantly administered oral medications. That does not prove a clinically significant interaction with LDN in every patient. It does justify documenting timing, formulation, symptom changes, and other oral therapies when multiple treatments are started or adjusted.

Weight change is not autoimmune disease control

Improved mobility or metabolic health may indirectly affect energy and quality of life. Those are meaningful outcomes, but they should not be relabeled as proof that a GLP-1 medicine treated Sjögren disease.

Retatrutide remains investigational

Retatrutide is not FDA approved and has not been found safe and effective for Sjögren disease or any other condition. FDA states that retatrutide cannot be used in compounding under federal law. It should not be marketed as a compounded alternative, a Sjögren treatment, or part of an LDN combination protocol.

Where the LDN Research Trust Fits

The LDN Research Trust has useful educational pages, interviews, and publication summaries that can help readers find the Sjögren case reports and understand why LDN is being discussed.

Its role should be defined carefully:

• Use it for research discovery and patient education.
• Pair it with the original PubMed-indexed papers.
• Do not use domain authority to upgrade a case report into controlled evidence.
• Do not use it alone for efficacy, safety, dosing, or standard-of-care claims.

That balanced approach preserves the value of the resource without overstating the underlying study design.

Personalized Compounding Does Not Prove a Better Outcome

Commercial naltrexone tablets are generally available at a much higher strength than doses commonly discussed as LDN. A compounding pharmacy may prepare a patient-specific strength or dosage form when a licensed prescriber determines that it is clinically appropriate.

Customization may help a prescriber align a formulation with an individualized plan. It does not prove that the medicine will improve Sjögren symptoms, reduce autoantibodies, restore gland function, or prevent systemic complications. Compounded preparations are not FDA approved, and a pharmacy should not imply otherwise.

Patients and clinicians can learn more about Scripx compounding services and should confirm current availability, prescription requirements, shipping eligibility, ingredients, and monitoring needs directly with the pharmacy.

A Responsible Monitored Trial Starts With One Defined Goal

If a clinician determines that an off-label trial is appropriate, monitoring should focus on outcomes that can actually be interpreted.

A practical baseline may include:

• the primary symptom being targeted;
• a 0–10 fatigue or pain rating;
• one or two functional measures;
• dryness severity documented separately;
• current ocular and oral treatments;
• sleep, hydration, nutrition, and activity;
• concurrent medication changes;
• opioid and procedure history;
• clinician-selected laboratory or disease-activity measures when relevant.

Avoid starting or changing several therapies at the same time when that can safely be avoided. Otherwise, any improvement or adverse effect becomes difficult to attribute.

The stop or reassessment criteria should also be defined in advance. Continued treatment should not depend on a vague hope that a response will eventually appear.

Symptoms That Need Prompt Evaluation

LDN discussions should not delay evaluation of symptoms that may signal a Sjögren complication or another condition. Prompt medical assessment may be appropriate for:

• new weakness, numbness, balance problems, or rapidly progressive nerve symptoms;
• new shortness of breath, persistent cough, or chest symptoms;
• severe eye pain, marked redness, light sensitivity, or vision change;
• persistent salivary-gland enlargement, a new mass, unexplained fever, night sweats, or weight loss;
• inability to maintain fluids, persistent vomiting or diarrhea, or signs of dehydration;
• jaundice, dark urine, or other symptoms of liver injury;
• pregnancy or pregnancy planning with anti-SSA or anti-SSB antibodies;
• anticipated surgery, dental procedures, or emergency pain needs while taking naltrexone.

Bottom Line

LDN for Sjögren disease is an evidence-limited, off-label discussion—not a proven autoimmune treatment.

Three published patients provide signals that fatigue, joint pain, general well-being, or inflammatory markers may improve for some individuals. The same literature does not establish a response rate, and the original case reported no meaningful improvement in dry eyes or dry mouth. There is no controlled evidence that LDN restores gland function, prevents neuropathy or organ involvement, reduces lymphoma risk, or modifies the long-term course of Sjögren disease.

The safest interpretation is also the most useful: define the symptom being targeted, protect established Sjögren care, review opioid and procedure risks, monitor function and tolerability, and keep GLP-1 therapy tied to its separate indication.

Ready for a pharmacist-supported medication review? Explore Scripx low-dose naltrexone options, read the complete LDN evidence and safety guide, explore Scripx weight-management services for a separate eligible metabolic goal, or contact Scripx. A prescription decision should follow individualized clinician review and should not replace rheumatology, ophthalmology, dental, neurologic, pulmonary, or other condition-specific care.

Educational content only. This article does not diagnose, prescribe, or establish that LDN or GLP-1 therapy is appropriate for any individual.

---

4. FAQ Package

1. Is LDN FDA approved for Sjögren disease?

No. Naltrexone is FDA approved for alcohol dependence and blockade of the effects of exogenous opioids at standard dosing. LDN use for Sjögren disease is off label.

2. How much direct evidence exists for LDN in Sjögren disease?

The published direct evidence consists of three patients described in two case-report papers from 2019 and 2020. A 2023 rheumatology review identified the same three cases. This is not enough to estimate a reliable response rate.

3. Did the published patients improve?

The reports described improvement in fatigue, joint pain, general well-being, or inflammatory markers in individual patients. Because the reports were uncontrolled and involved only three patients, they cannot establish that LDN caused the changes or predict who will respond.

4. Does LDN improve dry eyes or dry mouth?

That has not been established. The original case report specifically noted no significant change in dry eyes or dry mouth. LDN should not replace established ocular, dental, oral, or saliva-support care.

5. Can LDN restore salivary or tear-gland function?

No adequate evidence shows that LDN restores gland function or reliably increases tear or saliva production in Sjögren disease.

6. Does LDN modify the autoimmune disease?

That remains unproven. Changes in symptoms or inflammatory markers in a case report are not evidence that LDN prevents organ involvement, neuropathy, gland damage, lymphoma, or long-term disease progression.

7. Can LDN replace hydroxychloroquine, immunosuppressive therapy, or biologic treatment?

No comparative evidence supports substitution. Sjögren treatment is based on the specific manifestation, severity, and specialist evaluation. LDN has only been described as an off-label adjunct in case reports.

8. Can LDN be taken with opioid pain medicine?

Naltrexone blocks opioid effects and may precipitate withdrawal in someone who is opioid dependent. Opioid analgesics, tramadol, methadone, buprenorphine, opioid-containing cough or diarrhea products, and recent procedural opioids require clinician review before LDN is considered.

9. What if surgery or dental treatment is planned?

Tell the surgeon, dentist, anesthesiologist, pharmacist, and prescribing clinician that naltrexone is being used. Pain and medication plans may need advance coordination. Do not stop or restart medication without professional guidance.

10. Do semaglutide or tirzepatide treat Sjögren disease?

No. GLP-1 medicines may be prescribed for separate approved metabolic indications in eligible patients, but they are not established treatments for Sjögren disease, dryness, pain, fatigue, or autoimmune activity.

11. Why does GLP-1 coordination matter in Sjögren disease?

Nausea, vomiting, diarrhea, constipation, reduced intake, and volume depletion can complicate hydration, oral comfort, nutrition, fatigue, and medication attribution. Delayed gastric emptying may also affect some oral medications.

12. Can a compounding pharmacy prepare patient-specific LDN?

A compounding pharmacy may prepare a patient-specific strength or dosage form when a licensed prescriber determines that it is clinically appropriate. Customization does not prove efficacy, and compounded preparations are not FDA approved.

 

Prepared by: Scripx Pharmacy editorial team
Clinical review: Scripx Pharmacist
Last reviewed: September 25, 2026
Evidence cutoff: September 25, 2026